UT Houston Enrolls First Patient in Stem Cell Study for Stroke
News Apr 23, 2009
For the first time in the United States, a stroke patient has been intravenously injected with his own bone marrow stem cells as part of a research trial at The University of Texas Medical School at Houston.
Sean Savitz, M.D., assistant professor of neurology at The University of Texas Medical School at Houston, leads a first-of-its-kind bone marrow stem cell therapy study for stroke patients.
Roland “Bud” Henrich, 61, was transferred to Memorial Hermann – Texas Medical Center on March 25 after suffering a stroke while working on his farm in Liberty. He arrived too late to receive tissue plasminogen activator (tPA), the only treatment for ischemic strokes. He became the first patient in the trial.
The Phase I safety trial, funded with a pilot grant from The National Institutes of Health and support from the Notsew Orm Sands Foundation, will enroll nine more patients who have suffered a stroke and can be treated with the stem cell procedure within 24 to 72 hours of initial symptoms.
“It’s still very early in this safety study, but this could be an exciting new therapeutic approach for people who have just suffered a stroke,” said Sean Savitz, M.D., assistant professor of neurology at the medical school and the study’s lead investigator. “Animal studies have shown that when you administer stem cells after stroke, the cells enhance the healing. We know that stem cells have some kind of guidance system and migrate to the area of injury. They’re not making new brain cells but they may be enhancing the repair processes and reducing inflammatory damage.”
Roland "Bud" Henrich, 61, was the first stroke patient to be enrolled in a Phase I trial using his own stem cells.
Savitz said animal studies have shown that the healing effects of stem cells can occur as early as a week but cautioned it is too early to attribute Henrich’s improvement to the stem cell treatment. “I'm hoping he will get better and it will be because of the cells, but it's just hope at this point,” Savitz said.
The stem cells were harvested from the bone marrow in the iliac crest of his leg, then separated and returned to Henrich several hours later. Because they are his own stem cells, rejection is not expected to be an issue.
When he arrived at the hospital, Henrich could not speak and had significant weakness on his right side. When he was released after nearly two weeks of hospitalization and rehabilitation, he was able to walk and climb stairs unassisted and said his first words.
“This study is the critical first step in translating laboratory work with stem cells into benefit for patients. If effective, this treatment could be helpful to a huge segment of stroke patients to reduce their disability,” said James C. Grotta, M.D., Roy M. and Phyllis Gough Huffington Distinguished Professor of Neurology and chair of the Department of Neurology at the medical school. “We are fortunate here at UT Houston and the Texas Medical Center to have the resources needed to carry out this work, and to have attracted someone of Dr. Savitz’s caliber to lead this study.”
The study is only open to patients who are admitted to the Emergency Center at Memorial Hermann – TMC or through the UT Stroke Team with symptoms of an immediate stroke.
New Speakers from Roche and Imperial College London Announced for SMi’s ADMET EventNews
SMi Group Reports: With less than 4 weeks left until the 13th annual ADMET Conference commences in London, SMi announces two new speakers joining the event.READ MORE
Cell Technology Used to Treat Osteochondral Knee DefectNews
Autologous cells of stromal vascular fraction were transplanted to a 36-year-old man with the use of fibrin matrix.READ MORE
Gene Editing Technology May Improve Accuracy of Predicting Heart Disease RiskNews
Scientists may now be able to predict whether carrying a specific genetic variant increases a person’s risk for disease using gene editing and stem cell technologies.READ MORE